{"id":11449,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T09:00:32","modified_gmt":"2025-10-04T09:00:32","slug":"hipertermia-qualidade-de-vida-qdv","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-qualidade-de-vida-qdv\/","title":{"rendered":"Impacto da Hipertermia na Qualidade de Vida (QdV): Al\u00edvio da Dor, Redu\u00e7\u00e3o da Fadiga e Benef\u00edcios Imunol\u00f3gicos Adjuvantes"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Impacto da Hipertermia na Qualidade de Vida (QdV): Al\u00edvio da Dor, Redu\u00e7\u00e3o da Fadiga e Benef\u00edcios Imunol\u00f3gicos Adjuvantes\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermia, Oncologia, ensaio cl\u00ednico Fase III, QdV, dor, E-E-A-T\"\n      \/*... O Esquema FAQPage seria adicionado separadamente para a sec\u00e7\u00e3o Perguntas Frequentes *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoridade e Expertise (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Por <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, e <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Impacto da Hipertermia na Qualidade de Vida (QdV): Al\u00edvio da Dor, Redu\u00e7\u00e3o da Fadiga e Benef\u00edcios Imunol\u00f3gicos Adjuvantes<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Na oncologia moderna, a gest\u00e3o do cancro visa o equil\u00edbrio ideal entre<a href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-sobrevivencia-doentes\/\"> a Sobreviv\u00eancia (OS\/DFS)<\/a> e <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">a Qualidade de Vida (QdV).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> A Hipertermia (HT) representa uma modalidade adjuvante \u00fanica, demonstrada atrav\u00e9s de ensaios cl\u00ednicos importantes ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/pt-pt\/hipertermia-estudos-de-fase-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RCTs de Fase III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) que melhora a QdV em m\u00faltiplos n\u00edveis: controlo de sintomas, estado funcional geral e um excelente perfil de seguran\u00e7a.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Principal Benef\u00edcio Paliativo: Controlo da Dor (evid\u00eancia de n\u00edvel A1 de ensaios cl\u00ednicos de Fase III)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A dor \u00f3ssea metast\u00e1tica degrada a QdV. A Hipertermia RF Locorregional, combinada com a Radioterapia (RT), proporciona um controlo paliativo superior, de acordo com <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">o estudo Fase III publicado por Chi MS e col<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indicador QdV\/Melhoria da Dor<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapia<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermia (HT)<\/span><\/span><\/th>\n<th>Impacto QdV<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Taxa de Resposta Completa (CR) aos 3 Meses<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (pontua\u00e7\u00e3o de dor zero)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aumento de 533 % nas hip\u00f3teses de elimina\u00e7\u00e3o total da dor.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dura\u00e7\u00e3o do Al\u00edvio da Dor<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: 55 dias\/7,9 semanas<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: N\u00e3o alcan\u00e7ada \u00e0s 24 semanas<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A dura\u00e7\u00e3o do al\u00edvio triplica, reduzindo a depend\u00eancia de analg\u00e9sicos.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Em <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024, Sahinbas e colegas publicaram um estudo de Fase III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> para a dor de met\u00e1stases \u00f3sseas, principalmente de cancro da mama e da pr\u00f3stata, utilizando hipertermia WBHT wIRA em adi\u00e7\u00e3o \u00e0 RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Com base neste estudo, o grupo tratado apenas com radioterapia (RT) apresentou a dor mais intensa. O estudo foi conclu\u00eddo ap\u00f3s o recrutamento de um total de 61 pacientes, 5 anos ap\u00f3s o primeiro recrutamento (abril de 2016 a fevereiro de 2021). Finalmente, a taxa de CR no grupo RT + WBH mostrou a diferen\u00e7a mais significativa com a RT em monoterapia, 47,4% vs. 5,3%, respetivamente, dentro de 2 meses ap\u00f3s o tratamento (valor de P &lt; 0,05). O tempo at\u00e9 o al\u00edvio completo da dor foi de 10 dias para RT + WBH, enquanto o ponto final n\u00e3o foi atingido no grupo de RT em monoterapia. A progress\u00e3o da dor ou a estabilidade da doen\u00e7a foram observadas em metade dos pacientes no grupo RT dentro de 4 semanas ap\u00f3s o tratamento. No entanto, esta pontua\u00e7\u00e3o esteve perto de zero nos pacientes RT + WBHT dentro de dois meses ap\u00f3s o tratamento.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Conclus\u00f5es:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH mais RT demonstraram aumentos significativos no al\u00edvio da dor e um tempo de resposta mais curto em compara\u00e7\u00e3o com a RT isolada em pacientes com les\u00f5es \u00f3sseas metast\u00e1ticas.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indicador QdV\/Melhoria da Dor<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapia<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermia (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Impacto QdV<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Taxa de Resposta Completa (CR) aos 2 Meses<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (pontua\u00e7\u00e3o de dor zero)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aumento de 894 %<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * nas hip\u00f3teses de elimina\u00e7\u00e3o total da dor.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tempo at\u00e9 o al\u00edvio completo da dor<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">n\u00e3o foi alcan\u00e7ado<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dias<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">Benef\u00edcio Significativo e R\u00e1pido<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dura\u00e7\u00e3o do Al\u00edvio da Dor\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: 28 dias\/4 semanas em metade dos pacientes<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: N\u00e3o alcan\u00e7ada \u00e0s 24 semanas<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A dura\u00e7\u00e3o do al\u00edvio * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">multiplica-se por seis<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, reduzindo a depend\u00eancia de analg\u00e9sicos.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Melhoria do Estado Funcional e Redu\u00e7\u00e3o da Fadiga<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">O benef\u00edcio da HT na QdV \u00e9 diretamente mensur\u00e1vel atrav\u00e9s de question\u00e1rios padronizados (EORTC QLQ-C30), mostrando uma melhoria no estado geral (Fun\u00e7\u00e3o F\u00edsica, Fadiga e Ansiedade):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QdV Significativamente Melhorada (hipertermia RF modulada mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Um ensaio cl\u00ednico randomizado sobre Hipertermia RF Modulada (mEHT) no Cancro do Colo do \u00datero (LACC) relatou uma melhoria significativa nos scores de QdV a longo prazo, com pacientes a relatar melhores scores nas escalas de Fun\u00e7\u00e3o F\u00edsica e Emocional.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Controlo da Fadiga e Imunomodula\u00e7\u00e3o:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> A Hipertermia de Corpo Inteiro (WBHT) e a HT em geral influenciam positivamente a fadiga cr\u00f3nica (CRF) atrav\u00e9s da modula\u00e7\u00e3o de citocinas pr\u00f3-inflamat\u00f3rias (IL-6, TNF-alfa). A HT tamb\u00e9m ajuda a manter e melhorar os scores nas escalas de Fun\u00e7\u00e3o F\u00edsica e Emocional a longo prazo.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Recupera\u00e7\u00e3o Emocional R\u00e1pida (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ap\u00f3s grandes procedimentos cir\u00fargicos que incluem HT (HIPEC), a QdV emocional tende a melhorar rapidamente, come\u00e7ando logo ap\u00f3s *3 meses do p\u00f3s-operat\u00f3rio, muitas vezes excedendo os n\u00edveis de base.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Consolida\u00e7\u00e3o dos Benef\u00edcios de QdV a Longo Prazo<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Os dados do mundo real e os ensaios cl\u00ednicos em cancros avan\u00e7ados refor\u00e7am o papel da Hipertermia na estabiliza\u00e7\u00e3o e melhoria da QdV a longo prazo:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Impacto Curativo aos 12 Meses:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Uma an\u00e1lise exaustiva de pacientes tratados com inten\u00e7\u00e3o curativa (RCT + HT) mostrou uma melhoria significativa, mantida ao longo de um *per\u00edodo de 12 meses, nos scores nas subescalas de QdV que avaliam a **Fun\u00e7\u00e3o Emocional, a Fun\u00e7\u00e3o Social* e a *Ins\u00f3nia (SL)*, em compara\u00e7\u00e3o com a popula\u00e7\u00e3o de refer\u00eancia oncol\u00f3gica da EORTC.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Benef\u00edcios Paliativos:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Num contexto paliativo, a adi\u00e7\u00e3o de HT ao tratamento padr\u00e3o levou a uma melhoria clinicamente relevante da *Dor (PA)* e a uma redu\u00e7\u00e3o das *Dificuldades Financeiras (FI)* *3 meses ap\u00f3s o tratamento*, contribuindo para um melhor estado geral do paciente.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QdV Melhorada em Doen\u00e7a Avan\u00e7ada (Cancro Colorretal):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Num estudo que avaliou a Hipertermia de Alta Frequ\u00eancia assistida por Quimioterapia em pacientes com Cancro Colorretal em est\u00e1gio interm\u00e9dio e avan\u00e7ado, o grupo que recebeu a combina\u00e7\u00e3o mostrou scores de QdV significativamente mais altos (melhorados) ap\u00f3s 4 ciclos de tratamento, demonstrando que a HT melhora efetivamente a QdV, para al\u00e9m dos efeitos terap\u00eauticos, mantendo ao mesmo tempo uma melhor seguran\u00e7a.[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Benef\u00edcios Biol\u00f3gicos Adjuvantes e \u00cdndice Terap\u00eautico Superior<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A HT maximiza a letalidade do tratamento sem aumentar significativamente o risco de toxicidade grave (Grau 3-4), mantendo assim um elevado \u00cdndice Terap\u00eautico:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Seguran\u00e7a Validada (ensaios cl\u00ednicos Fase III):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> As meta-an\u00e1lises no Cancro do Colo do \u00datero demonstram nenhuma diferen\u00e7a significativa na toxicidade aguda ou tardia (RR Toxicidade 1.01)[6]. O perfil de seguran\u00e7a \u00e9 mantido no Cancro Retal [7]e nos ensaios sobre Cancro do P\u00e2ncreas.[8]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Preserva\u00e7\u00e3o de \u00d3rg\u00e3os:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> No Cancro Retal, a adi\u00e7\u00e3o de HT \u00e0 quimiorradioterapia neoadjuvante aumenta a Sobreviv\u00eancia Livre de Colostomia (CFS) aos 5 anos de 69,0 % para 87,7 %, um benef\u00edcio funcional importante para a QdV.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Efeito Abscopal (Tipo Vacina):<\/strong> A HT desencadeia a morte celular imunog\u00e9nica, libertando Prote\u00ednas de Choque T\u00e9rmico (HSPs) que ativam as c\u00e9lulas T CD8+ citot\u00f3xicas. Esta inicia\u00e7\u00e3o imunol\u00f3gica sist\u00e9mica contribui para o controlo da doen\u00e7a residual e \u00e9 um benef\u00edcio adjuvante essencial.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Conclus\u00e3o: Terapia Centrada no Paciente<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A integra\u00e7\u00e3o da Hipertermia no protocolo oncol\u00f3gico representa uma estrat\u00e9gia avan\u00e7ada, baseada em evid\u00eancias, que n\u00e3o s\u00f3 melhora a Sobreviv\u00eancia, mas tamb\u00e9m proporciona um controlo robusto dos sintomas e mant\u00e9m a Qualidade de Vida. O al\u00edvio da dor, o controlo da fadiga e um excelente perfil de seguran\u00e7a tornam a HT um elemento essencial dos cuidados hol\u00edsticos do paciente oncol\u00f3gico.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Convidamo-lo a consultar os nossos especialistas para integrar a Hipertermia no seu protocolo, com o objetivo de maximizar tanto a efic\u00e1cia como a Qualidade de Vida.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Garantia EEAT:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Este conte\u00fado \u00e9 baseado em dados publicados de ensaios cl\u00ednicos randomizados de Fase III e prospetivos, utilizando instrumentos padr\u00e3o de medi\u00e7\u00e3o da Qualidade de Vida (EORTC QLQ-C30). As refer\u00eancias completas s\u00e3o integradas com links diretos para as publica\u00e7\u00f5es fonte.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Refer\u00eancias:<\/span><\/span><\/p>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoridade e Expertise (EEAT): Por Dr. Veronica Iatan , MD, e Cristian Gologan M.Sc , Andromedichyperthermia Impacto da Hipertermia na Qualidade de Vida (QdV): Al\u00edvio da Dor, Redu\u00e7\u00e3o da Fadiga e Benef\u00edcios Imunol\u00f3gicos Adjuvantes Na oncologia moderna, a gest\u00e3o do cancro visa o equil\u00edbrio ideal entre a Sobreviv\u00eancia (OS\/DFS) e a Qualidade de Vida (QdV).&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[176,25,983],"tags":[984,1072,985,1071,313,986,793,1073,990],"class_list":["post-11449","post","type-post","status-publish","format-standard","hentry","category-news-pt-pt","category-sem-categoria","category-studii-clinice-pt-pt","tag-calitatea-vietii-pt-pt","tag-dor","tag-durere-pt-pt","tag-ensaio-clinico-fase-iii","tag-hipertermia-pt-pt","tag-hipertermie-oncologica-pt-pt","tag-oncologia-pt-pt","tag-qdv-pt-pt","tag-studii-faza-iii-pt-pt"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/posts\/11449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=11449"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/posts\/11449\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=11449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/categories?post=11449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=11449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}